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Background: Dickoppf-1 (DKK-1) is a negative regulator of bone formation with tumorigenic potential. The
up-regulation of DKK-1 is an early event in prostate cancer (PCa) development, thus we investigated its role as a
marker in the diagnosis and prognosis of PCa.
Methods: We retrospectively enrolled 159 patients who underwent prostate biopsy, either for elevated PSA or
suspect digital rectal examination, between 2003 and 2010. During the biopsy, one serum sample was collected
from all patients; PSA and DKK-1 were measured by ELISA technique. Amongst the biopsy of 159 patients 75 were
affected by PCa and 84 were not the mean period of follow-up for these patients was 5 years; a new biopsy was
performed in case of PCa suspicion.
Results: PSA performed better than DKK-1 in detecting PCa (0.63 vs 0.51 respectively). Differently from PSA DKK-1
was significantly higher in patients who developed PCa during follow-up than in cancer-free ones, thus DKK-1
performed better than PSA in detecting these patients (0.67 vs 0.55). DKK-1 was significantly lower in patients with
bone metastases, whereas PSA was not significantly different in patients with different outcomes.
Conclusions: DKK-1 might be predictive for patients negative at first biopsy who will develop PCa and in the
prognosis of bone metastases. It performed worse than PSA in the early diagnosis of Pca.
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Prostate-specific antigen (PSA) is the most famous and
debated cancer marker in the urological field. The
recommendations of the European Association of
Urology (EAU) Guidelines on Prostate Cancer (PCa)
state that the main diagnostic tools for PCa include
digital rectal examination (DRE), serum PSA level and
trans-rectal ultrasounds (TRUS) [1]. Increasing levels of
PSA are associated with an enhanced risk of the disease,
but presently there is no upper or lower threshold limit [2].
PCa is currently the most frequently diagnosed cancer
in males and constitutes a major health issue in developed
countries, but the majority of PCa cases are considered
clinically not significant and certainly not lethal. These
discrepancies highlight the need for the early detection of
PCa, especially for cases with aggressive features, which
require an early and radical intervention. In these patients* Correspondence: patrizia.damelio@unito.it
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reproduction in any medium, provided the orPSA is inadequate since it is prostate specific, but not
a PCa specific marker: PSA increases in other common
prostate diseases such as benign hyperplasia and prostatitis
or after procedures as TRUS, biopsy and after transurethral
prostatectomy. The use of PSA for predicting cancer
aggressiveness and outcome is effective only for high
PSA levels (>20 ng/mL) combined with Gleason score
higher than 8 [3].
Continuous effort is made to find new reliable markers
for the diagnosis and the prognosis of PCa, especially for
PCa with low malignancy at histological evaluation.
Among the potential markers, Dickoppf-1 (DKK-1) has
shown interesting evidences, since its levels has been
found elevated in different cancer types, such as multiple
myeloma, gastric, lung, oesophageal and breast cancer [4-9]
DKK-1 is a secreted inhibitor of the Wnt signalling pathway,
which has tumorigenic and osteogenic potential [10-15].
Wnt proteins physiologically induce the differentiation
and maturation of osteoblasts [16] and the secretion
of Wnt proteins was shown to increase bone formation in
osteoblastic metastases [17]. DKK-1 is a negative regulatoral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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it is also involved in the proliferation of stem cells and
tumorigenic processes [10-15].
The expression of DKK-1 in PCa samples is conflicting,
because literature data report either an increase [18] or a
non-significant change [19] in PCa samples. Recently an
elegant study by Thudi et al. demonstrated a significant role
for DKK-1 in PCa growth and ability to metastasise [12].
The present study aims to evaluate the potential
usefulness of DKK-1 in diagnosis and prognosis of PCa
patients with PSA levels lower than 20 ng/ml.
Methods
This is a retrospective study, approved by the Ethical
Committee of our Hospital (“Comitato Etico Interaziendale
A.O.U. Città della Salute e della Scienza di Torino - A.O.
Ordine Mauriziano - A.S.L. TO1”, that includes 159
men who underwent prostate biopsy due to suspicion
of PCa, either for elevated PSA or suspect digital rectal
examination, between 2003 and 2010. Patients consent to
prostate biopsy, to collect and froze the serum was
obtained at enrollment. Among this 159 men 75 were
diagnosed with PCa and 84 were cancer free at biopsy.
During biopsy a serum sample was collected and frozen at
80°C.We included in the study sera from patients with
PSA lower than 20 ng/ml. DKK-1 levels were determined
by a commercially available ELISA (BioMedica, Italy) in
accordance with manufacturer instructions. The variability
within- and between-run ranged from 6.5% to 8.0% and
from 9.1% to 12.3%, respectively. PSA concentrations were
assessed by electrochemiluminesce-based immunoassay
automated on Cobas® analyzer (Roche Diagnostics GmbH,
Mannheim, Germany).
The mean follow-up period for patients was 5 years
(range 6 months-9 years); 28 subjects (17.6%) did not
come back to follow-up, 12 of them died. The majority
of subjects lost to follow-up were cancer free (Figure 1).Figure 1 Survival curves show the availability of PCa patients
(continuous line) and controls (dotted line) at follow-up the
p value is showed.Follow-up consists of PSA measurement and DRE. A
new biopsy was performed whether PSA rose: there was
a suspect DRE or there was a previous diagnosis of atypical
acinar proliferation. All PCa patients except for one, were
subjected to radical treatment, either radical prostatectomy
or radiotherapy.
During follow-up we identified 13 new PCa among
subjects cancer free at enrolment.
In order to evaluate the prognostic role of DKK-1,
patients were classified as: never had cancer, PCa-free,
local recurrence, bone metastases, metastases other
than bone at the last available follow- up. Among the
12 patients who died during follow-up only 4 died for
cancer (6.8%).
Statistical analyses
PCa patients and controls were compared for age: DKK-1
by means of one way ANOVA and PSA by means of
Mann–Whitney test.
In order to evaluate prognostic value of DKK-1 as
compared to PSA, patients and disease outcomes were
compared for different values of PSA and DKK-1 after
weighting cases for the follow-up period.
The Receiver Operating Characteristic (ROC) curves
for PSA and DKK-1 were built and the area under ROC
curves (AUROCs) compared both for diagnosis and
prognosis.
SPSS 20.0 for windows software was used for statistical
analyses; p values were considered significant when
equal or lower than 0.05. Prism Graph Pad 6.02 for
Windows was used to draw graphs.
Results
DKK-1 and PSA in PCa diagnosis
PCa patients (75) and controls (84) were comparable for
age and DKK-1 serum levels, whereas PSA was significantly
lower in non-cancer patients (Figure 2A, B). In order to
evaluate whether PSA performed better than DKK-1 we
carried out a ROC analysis, the PSA AUROC was slightly,
although non-significantly, better that DKK-1 AUROC
(Figure 2C).
The use of the ROC analyses allowed us to compare
the diagnostic potential of PSA and DKK-1, the similar
AUROC confirms that PSA lower than 20 ng/ml is not
useful in the diagnosis of PCa.
DKK-1 measured at diagnosis is lower in patients
developing bone metastasis during follow-up
At the last available follow-up, 75% of PCa patients
were cancer free, 15.8% had local recurrence, 8.8%
had osteoblastic bone metastases, 3.5% had metastases
other than bone and 7% were dead for cancer related
reasons. PCa patients’ outcomes were compared for
PSA, Gleason score and DKK-1 after weighting cases for
Figure 2 Scatter plots show the level of PSA (panel A) and DKK-1 (panel B) in PCa patients and controls (significant p value is shown). Panel C
show the Receiver Operator Curves (ROC) for PSA (dotted line) and DKK-1 (continuous line), Area Under ROC (AUROCs) with CI are shown.
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was not significantly different amongst different outcomes
(Figure 3A), whereas DKK-1, measured at diagnosis, was
reduced in patients that developed bone lesions during
follow up (Figure 3B). Gleason score was higher in
patients with local recurrence and in those developing
bone metastases (Figure 3C).Figure 3 Graphs show PSA (panel A), DKK-1 (panel B) and Gleason sc
mean and standard errors, p values were calculated with one way ANOVA for
cases for period of follow-up.DKK-1 allow to identify new PCa at follow-up
Among subjects with negative bioptic findings at en-
rolment, 13 (15.5%) developed PCa. DKK-1 signifi-
cantly increased in these patients, whereas PSA did
not (Figure 4A,B). DKK-1 performed better than PSA,
even though the AUROC was similar amongst the
two markers (Figure 4C).ore (panel C) in relation with disease outcomes. Bars represent
DKK-1 and Gleason; with Mann–Whitney test for PSA after weighting
Figure 4 Scatter plots show the level of DKK-1 (panel A) and PSA (panel B) in controls cancer- free at follow-up, and in patients with new
diagnosed PCa (significant p value is shown). Panel C shows the ROC curves for PSA (dotted line) and DKK-1 (continuous line), with AUROCs and CI.
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PCa is the most frequently diagnosed cancer in males, but
very often it is not highly invasive. The wide adoption of
PSA screening has been proved to increase diagnosis, to
induce over treatment, to cause anxiety, treatment adverse
events and to reduce the quality of life of patients [20,21].
For these reasons continuous efforts are made to identify
new more reliable markers for the diagnosis and prognosis
of PCa other than PSA.
It is well known that aggressive PCa very often causes
bone metastases [22], which are typically characterized
by excessive bone formation: highly active osteoblasts
form structurally weak and sclerotic bones at high risk
of fracture. DKK-1 is a fundamental inhibitor of the Wnt
pathway [10], controlling the formation and activity
of osteoblasts, and it is impaired in osteoblastic bone
metastases [7,23].
Recently DKK-1, as a molecule involved in the control
of bone formation, has shown to be involved in PCa
biology and in its propensity to develop bone metastases
[12]. We previously showed that DKK-1 was elevated in
sera of PCa patients [18]. DKK-1 was directly produced
by PCa cells, whereas normal prostate tissue did not
produce this molecule [18]. In the present study, DKK-1
was not significantly higher in PCa patients than in
controls, appearing discordant by the above reported
data, nevertheless this may be explained by the different
origin of the control group. Indeed, now we compared
PCa patients to subjects showing an increased PSA with a
benign prostatic disease, whereas in the previous study the
control group was constituted by healthy subjects [18].
Here we show that DKK-1 is decreased in PCa patientswho will develop bone metastases, whereas PSA is not
significantly different in these set of patients. These data
are consistent with the role of DKK-1 in the control of
cancer progression and of bone formation. A recent study
by Thudi et al. demonstrated that in PCa over expressing
DKK-1 there was an increased in the growth and
metastatic activity of PCa cells but a decreased bone
formation in bone metastases [12]. These results confirmed
previous data showing that DKK-1 expression is an early
event in PCa. During PCa progression DKK-1 expression
decreases, particularly in advanced bone metastases [24].
These data support a model in which DKK-1 acts as
a molecular switch promoting the transition of bone
lesions from osteolytic to osteoblastic [24]. The biological
functions of DKK-1 in the bone metastatic process and in
tumor progression suggest its potential therapeutic role as
a target [25].
DKK-1 did not add significant information to PSA in
the early detection of PCa, although the AUROC for
DKK-1 and PSA was comparable. This result should be
considered despite several limitations of the study, such
as the retrospective design, the small number of patients
enrolled and the short follow-up, considering the long
natural history of PCa. Noteworthy, we showed that
DKK-1 was more elevated in patients with negative
bioptic finding further developed PCa during follow-up,
whereas PSA was not significantly different in these
subjects at enrollement. The potential ability of DKK-1
to detect PCa patients with higher risk of progression
would add valuable information to the risk stratification in
clinical practice. This is particular important in order to
increase the ability to predict PCa development; although
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up, the ROC analyses showed that DKK-1 performed
slightly better than PSA in detecting these patients. Our
results confirmed literature data reporting the role of
DKK-1 as a potential serological biomarker in different
tumors such as gastric cancer [26], hepatocellular
carcinoma [27,28], non-small cell lung cancer [29]
and gynaecological cancer [5].
Our findings need to be confirmed in a larger cohort
of patients. DKK-1 could be useful in the difficult
management of patients with suspicion of harbouring
PCa despite a previously negative biopsy. Such patients
are a challenge for the urologists: after an initial negative
bioptic finding, a further biopsy has shown to be positive
in 10-35% of cases [30].
Conclusion
In summary, our study unravelled a potential utility of
DKK-1 in the diagnostic process of PCa. Indeed, in our
cohort of patients, DKK-1 detects patients with high risk of
PCa progression and a previous negative biopsy. Further
studies on larger scale are surely warranted, keeping in
mind that this marker could also represent an interesting
therapeutic target to disrupt the metastatic process of PCa.
Abbreviation
DKK-1: Dickoppf-1; PCa: Prostate cancer; PSA: Prostate-specific antigen;
DRE: Digital rectal examination.
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